U.S. Government Secures $36.9M of Shionogi’s Fetroja for Biothreat Preparedness
Event summary
- BARDA exercised a $36.9M procurement option under Project BioShield for Shionogi’s Fetroja (cefiderocol) to combat drug-resistant bacterial threats.
- The order is part of a $119M initial contract with multiyear options totaling up to $482M.
- Funding supports U.S. manufacturing expansion, pediatric indications, and biothreat pathogen research.
- Fetroja is FDA-approved for complicated UTIs and hospital-acquired pneumonia in adults.
The big picture
The procurement underscores growing government investment in antimicrobial resistance preparedness, with Shionogi positioning Fetroja as a cornerstone asset. The deal’s scale ($36.9M initial, $482M potential) signals confidence in biothreat countermeasures as a strategic priority. Shionogi’s partnerships with GARDP and CHAI further highlight the industry’s push for equitable antibiotic access.
What we're watching
- Procurement Scale
- Whether BARDA’s $482M total option reflects sustained U.S. demand for biothreat countermeasures.
- Pediatric Expansion
- The pace at which Shionogi secures FDA approval for Fetroja in pediatric patients.
- Manufacturing Risk
- How quickly Shionogi establishes U.S. production capacity to meet potential BioShield demand.
Related topics